Xbrane Bioscience develops novel technologies for protein production and vaccine development
Xbrane Bioscience develops novel technologies for protein production and vaccine development
Xbrane Bioscience is developing a portfolio of innovative technologies, including platforms for the development of multivalent vaccines and the efficient production of proteins.
We aim to simplify your protein production - make it faster and easier.
We offer two novel Escherichia coli protein expression systems; Xbrane Lemo System™ and Xbrane Rhamex System™.
Do you want to follow us? Improve your protein yields now!
Sign up for our newsletter here! Contact us for more info.
2012-03-05: Xbrane Bioscience receives 1,25 million SEK grant from Vinnova for collaborative vaccine project.
2011-11-28: Article about Xbrane Bioscience's vaccine candidate in Svenska Dagbladet.
2011-09-29: EU invests €30 million to boost vaccine research.
2011-09-22: Xbrane Bioscience wins Incubator Export Challenge 2011.
2011-08-16: New vectors for tunable protein expression from Xbrane Bioscience.
An E. coli-based 'all-in-one' protein expression system compatible with all pET vectors that conveniently allows optimization of the overexpression of any given protein using a single strain rather than a multitude of strains.
A novel rhamnose-inducible protein expression system which is tightly regulated at the individual cell level, but at the same time is capable of achieving high protein yields.
Xbrane Bioscience AB is a Swedish spin-off from the world-leading Center for Biomembrane Research (CBR) at Stockholm University, Sweden. Read more>